|Articles|November 1, 2007

Pharmacy Times

  • Volume 0
  • 0

TEVA SETTLES PATENT CHALLENGE OF GSK DRUGS

Teva Pharmaceutical IndustriesLtd has resolved itspatent dispute with GlaxoSmithKline (GSK) via a settlement that will allow the Israel-basedgeneric drug maker to enter the US market with itsgeneric versions of 3 GSK diabetes drugs: Avandia (rosiglitazonemaleate), Avandamet (rosiglitazone maleate and metforminHCl), and Avandaryl (rosiglitazone maleate andglimepiride) oral tablets. Although details of the settlementwere held confidential by both parties, it was disclosed thatTeva could begin US marketing of the GSK drugs late in thefirst quarter of 2012. GSK filed several lawsuits challengingTeva?s plans to market generic versions of its drugs, and atrial in federal court had been scheduled to begin in August.

Articles in this issue

almost 18 years ago

Understanding the Metabolic Syndrome

almost 18 years ago

can you READ these Rxs?

almost 18 years ago

Case Studies

almost 18 years ago

compounding HOTLINE

almost 18 years ago

HYPERTENSION WATCH

almost 18 years ago

DIABETES WATCH

almost 18 years ago

CHOLESTEROL WATCH

almost 18 years ago

ASTHMA WATCH

almost 18 years ago

ARTHRITIS WATCH

Newsletter

Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.


Latest CME